Rabbit Polyclonal FGFR1 Antibody

Fibroblast Growth Factor Receptor 1 (FGFR1) is a transmembrane tyrosine kinase receptor that plays a critical role in regulating cell proliferation, differentiation, survival, and angiogenesis by binding to fibroblast growth factors (FGFs). Dysregulation of FGFR1 signaling, through gene amplification, mutations, or overexpression, is implicated in various cancers (e.g., breast, lung, and gastric cancers) and developmental disorders. FGFR1-targeted antibodies are therapeutic agents designed to inhibit aberrant FGFR1 activity by blocking ligand binding, receptor dimerization, or downstream signaling pathways like MAPK and PI3K/AKT. These monoclonal antibodies (e.g., bemarituzumab) often target the extracellular domain of FGFR1. offering specificity to minimize off-target effects. In oncology, FGFR1 antibodies are explored in clinical trials for tumors with FGFR1 alterations, either as monotherapies or in combination with chemotherapy/immunotherapy. Challenges include addressing resistance mechanisms, tumor heterogeneity, and balancing efficacy with toxicity. Beyond therapy, FGFR1 antibodies serve as diagnostic tools to detect receptor overexpression in patient tissues, aiding in biomarker-driven treatment strategies. Their development highlights the growing emphasis on precision medicine to target molecular drivers of disease.